ASH 2024: Select Abstracts of Key Advances in AML
References

Abstract #1569: Tsui SP, et al. Measurable Residual Disease Detection on Day 30 Post Haematopoietic Stem Cell Transplantation Predicts Clinical Outcome in Acute Myeloid Leukemia. *Blood.* 2024;144 (Supplement 1):1569.
doi: https://doi.org/10.1182/blood-2024-210964

Abstract #225: Jimenez-Vicente C, et al. Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations. *Blood.* 2024;144 (Supplement 1):225.
doi: https://doi.org/10.1182/blood-2024-204503

Abstract #1396: Byrd JC, et al. A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134). *Blood.* 2024;144 (Supplement 1):1396.
doi: https://doi.org/10.1182/blood-2024-211491

Abstract #217: Chua CC, et al. A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial. *Blood*. 2024;144 (Supplement 1):217.
doi: https://doi.org/10.1182/blood-2024-199882

Abstract #450: Zale A, et al. A Retrospective Analysis of Intensive Chemotherapy Vs. Venetoclax/Hypomethylating Agents for Patients Aged 60-75 with Favorable-Risk, NPM1-Mutated AML. *Blood*.2024;144 (Supplement 1):450.
doi: https://doi.org/10.1182/blood-2024-210320

Abstract #61: Ayoub E, et al. Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in *TP53* Mutant AML Clones. *Blood*. 2024;144 (Supplement 1):61.
doi: https://doi.org/10.1182/blood-2024-211845

Abstract #372: Zhang R, et al. Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia. *Blood*. 2024;144 (Supplement 1):372.
doi: https://doi.org/10.1182/blood-2024-205192

Abstract #216: Issa GC, et al. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. *Blood*. 2024;144 (Supplement 1):216.
doi: https://doi.org/10.1182/blood-2024-204375

Abstract #212: Searle E, et al. Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with *KMT2A* and *NPM1* Alterations. *Blood*. 2024;144 (Supplement 1):212.
doi: https://doi.org/10.1182/blood-2024-207106

Abstract #968: Gibson B, et al. Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial. *Blood*. 2024;144 (Supplement 1):968.
doi: https://doi.org/10.1182/blood-2024-198419

Abstract #4286: Borate U, et al. A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia. *Blood*. 2024;144 (Supplement 1):4286.
doi: https://doi.org/10.1182/blood-2024-210605

Abstract #2907: Canham J, et al. Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 'Midotarg Pilot'. *Blood*. 2024;144 (Supplement 1):2907.
doi: https://doi.org/10.1182/blood-2024-205133

Abstract #1508: Iat A, et al. Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. *Blood*. 2024;144 (Supplement 1):1508.
doi: https://doi.org/10.1182/blood-2024-207045

Abstract #733: DeAngelo DJ, et al. Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial. *Blood*. 2024;144 (Supplement 1):733.
doi: https://doi.org/10.1182/blood-2024-209097

Abstract #2883: Marvin-Peek J, et al. Clinical Outcomes Using Frontline "Triplet" Regimens for Newly Diagnosed *IDH*-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials. *Blood*. 2024;144 (Supplement 1):2883.
doi: https://doi.org/10.1182/blood-2024-200387

Abstract #63: Panah MJN, et al. Abundance of Relapse-Predictive Cells Can be Estimated at Diagnosis and Is Strongly Associated with Outcome in Pediatric AML. *Blood*. 2024;144 (Supplement 1):63.
doi: https://doi.org/10.1182/blood-2024-206142

Abstract #4255: Daver N, et al. Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML. *Blood*. 2024;144 (Supplement 1):4255.
doi: https://doi.org/10.1182/blood-2024-200397

Abstract #1007: Nguyen D, et al. Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. *Blood*. 2024;144 (Supplement 1):1007.
doi: https://doi.org/10.1182/blood-2024-208684

Abstract #1564: Borate U, et al. Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with *NPM1* Mutations or *KMT2A* rearrangements from the Beat AML Master Clinical Trial. *Blood*. 2024;144 (Supplement 1):1564. doi: https://doi.org/10.1182/blood-2024-211261

Abstract #3585: Duparc H, et al. AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model. *Blood*. 2024;144 (Supplement 1):3585. doi: https://doi.org/10.1182/blood-2024-208179

Provided by MediCom Worldwide, Inc.
Supported by an educational grant from Pfizer, Inc.